{"hands_on_practices": [{"introduction": "Before a new companion diagnostic (CDx) can be implemented, its performance must be rigorously compared against an existing reference method, such as Next-Generation Sequencing. When a perfect \"gold standard\" for the true clinical state isn't available, we rely on measures like Positive and Negative Percent Agreement (PPA/NPA) to quantify this concordance. This exercise [@problem_id:5009067] guides you through calculating these fundamental metrics from a concordance table, a core skill for establishing the analytical validity of a new assay for regulatory and clinical purposes.", "problem": "A biotechnology company is developing a Companion Diagnostic (CDx) for a predictive biomarker intended to guide therapy selection in a translational medicine program. The CDx is a polymerase chain reaction assay intended to detect a clinically actionable variant that is also measured by a comparator Next-Generation Sequencing (NGS) assay. In a blinded, prospectively collected study of $N$ specimens, the company obtains a $2 \\times 2$ concordance classification between the CDx and the NGS comparator, where counts are defined by joint outcomes: $n_{++}$ for CDx positive and NGS positive, $n_{+-}$ for CDx negative and NGS positive, $n_{-+}$ for CDx positive and NGS negative, and $n_{--}$ for CDx negative and NGS negative. There are no indeterminate results in this dataset.\n\nThe observed counts are: $n_{++} = 142$, $n_{+-} = 6$, $n_{-+} = 19$, $n_{--} = 843$, with total $N = n_{++} + n_{+-} + n_{-+} + n_{--}$.\n\nUsing only foundational frequency-based definitions of conditional probability for agreement metrics in assay comparisons, compute the positive percent agreement with the comparator, the negative percent agreement with the comparator, and the overall percent agreement between assays. Express each result as a decimal and round each to four significant figures. Provide your final results in the order: positive percent agreement, negative percent agreement, overall percent agreement.", "solution": "The problem requires the calculation of three agreement metrics for a Companion Diagnostic (CDx) assay compared to a Next-Generation Sequencing (NGS) comparator assay. The data are provided as counts in a $2 \\times 2$ classification table. Let $T$ denote the test assay (CDx) and $R$ denote the reference or comparator assay (NGS). A positive result is denoted by $+$ and a negative result by $-$. Based on the problem's explicit definitions:\n- $n_{++}$: The number of specimens that are CDx positive and NGS positive, i.e., Count($T^{+}, R^{+}$).\n- $n_{+-}$: The number of specimens that are CDx negative and NGS positive, i.e., Count($T^{-}, R^{+}$).\n- $n_{-+}$: The number of specimens that are CDx positive and NGS negative, i.e., Count($T^{+}, R^{-}$).\n- $n_{--}$: The number of specimens that are CDx negative and NGS negative, i.e., Count($T^{-}, R^{-}$).\n\nThe given counts are:\n$n_{++} = 142$\n$n_{+-} = 6$\n$n_{-+} = 19$\n$n_{--} = 843$\n\nThe total number of specimens, $N$, is the sum of these counts:\n$$N = n_{++} + n_{+-} + n_{-+} + n_{--} = 142 + 6 + 19 + 843 = 1010$$\n\nTo facilitate the calculations, we can organize these counts into a standard $2 \\times 2$ contingency table with the test assay (CDx) as rows and the comparator assay (NGS) as columns.\n\n| | **NGS Positive ($R^{+}$)** | **NGS Negative ($R^{-}$)** | **Row Total** |\n| :--- | :---: | :---: | :---: |\n| **CDx Positive ($T^{+}$)** | $n_{++} = 142$ | $n_{-+} = 19$ | $161$ |\n| **CDx Negative ($T^{-}$)** | $n_{+-} = 6$ | $n_{--} = 843$ | $849$ |\n| **Column Total** | $N_{R+} = 148$ | $N_{R-} = 862$ | $N = 1010$ |\n\nThe total number of specimens positive by the NGS comparator is $N_{R+} = n_{++} + n_{+-} = 142 + 6 = 148$.\nThe total number of specimens negative by the NGS comparator is $N_{R-} = n_{-+} + n_{--} = 19 + 843 = 862$.\n\nThe problem asks for the calculation of Positive Percent Agreement (PPA), Negative Percent Agreement (NPA), and Overall Percent Agreement (OPA) using foundational frequency-based definitions of conditional probability.\n\n1.  **Positive Percent Agreement (PPA)**: This metric quantifies the agreement for positive results. It is defined as the conditional probability that a specimen is positive by the CDx assay, given that it is positive by the NGS comparator.\n$$PPA = P(T^{+} | R^{+}) = \\frac{\\text{Count}(T^{+} \\cap R^{+})}{\\text{Count}(R^{+})}$$\nIn terms of the given counts:\n$$PPA = \\frac{n_{++}}{n_{++} + n_{+-}}$$\nSubstituting the numerical values:\n$$PPA = \\frac{142}{142 + 6} = \\frac{142}{148} \\approx 0.959459...$$\nRounding to four significant figures, we get $PPA = 0.9595$.\n\n2.  **Negative Percent Agreement (NPA)**: This metric quantifies the agreement for negative results. It is defined as the conditional probability that a specimen is negative by the CDx assay, given that it is negative by the NGS comparator.\n$$NPA = P(T^{-} | R^{-}) = \\frac{\\text{Count}(T^{-} \\cap R^{-})}{\\text{Count}(R^{-})}$$\nIn terms of the given counts:\n$$NPA = \\frac{n_{--}}{n_{-+} + n_{--}}$$\nSubstituting the numerical values:\n$$NPA = \\frac{843}{19 + 843} = \\frac{843}{862} \\approx 0.977958...$$\nRounding to four significant figures, we get $NPA = 0.9780$.\n\n3.  **Overall Percent Agreement (OPA)**: This metric quantifies the proportion of all specimens for which the two assays give the same result (concordance).\n$$OPA = \\frac{\\text{Count}(\\text{Concordant Results})}{\\text{Total number of specimens}}$$\nConcordant results are those where both assays are positive ($n_{++}$) or both are negative ($n_{--}$).\n$$OPA = \\frac{n_{++} + n_{--}}{N} = \\frac{n_{++} + n_{--}}{n_{++} + n_{+-} + n_{-+} + n_{--}}$$\nSubstituting the numerical values:\n$$OPA = \\frac{142 + 843}{1010} = \\frac{985}{1010} \\approx 0.975247...$$\nRounding to four significant figures, we get $OPA = 0.9752$.\n\nThe final results, rounded to four significant figures as requested, are:\n- Positive Percent Agreement ($PPA$) = $0.9595$\n- Negative Percent Agreement ($NPA$) = $0.9780$\n- Overall Percent Agreement ($OPA$) = $0.9752$", "answer": "$$ \\boxed{ \\begin{pmatrix} 0.9595 & 0.9780 & 0.9752 \\end{pmatrix} } $$", "id": "5009067"}, {"introduction": "While sensitivity and specificity measure a test's intrinsic accuracy, its real-world clinical utility is profoundly influenced by the patient population. The Positive Predictive Value (PPV)—which answers the crucial question, \"Given a positive result, what is the probability the patient truly has the biomarker?\"—is highly dependent on the prevalence of that biomarker. This problem [@problem_id:5009047] utilizes Bayes' theorem to demonstrate how enriching a study population can dramatically alter the confidence in a diagnostic result, a critical concept for interpreting test outcomes and designing effective patient stratification strategies.", "problem": "A biotechnology company is advancing a Companion Diagnostics (CDx) assay intended to identify patients with a therapeutically actionable kinase domain mutation for eligibility to a targeted therapy in translational medicine. In an early single-center Phase II study, the biomarker prevalence was $p = 0.05$, while in a later multicenter rollout, enriched pre-screening increased the prevalence to $p = 0.20$. The test has sensitivity $Se = 0.95$ and specificity $Sp = 0.98$. Positive Predictive Value (PPV) is defined as the probability that a patient truly has the biomarker given a positive test result. Sensitivity is defined as $P(+ \\mid D)$, specificity is defined as $P(- \\mid \\neg D)$, and prevalence $p$ is defined as $P(D)$, where $D$ denotes true biomarker presence and $+$ denotes a positive CDx result.\n\nStarting from Bayes’ theorem and from the core definitions of sensitivity, specificity, and prevalence in diagnostic testing, derive an expression for the Positive Predictive Value $PPV(p)$ as a function of $p$, $Se$, and $Sp$. Then, using $Se = 0.95$ and $Sp = 0.98$, compute the numerical change in $PPV$ when prevalence increases from $p = 0.05$ to $p = 0.20$. Express your final numeric answer as a decimal with no units, and round to four significant figures. Briefly interpret, in words, the clinical impact of this change for real-world CDx-guided therapy allocation without using percentage signs.", "solution": "The objective is to derive an expression for the Positive Predictive Value, $PPV$, and then to calculate its change for two different values of prevalence, $p$. The $PPV$ is defined as the conditional probability of a patient having the biomarker ($D$) given that the test result is positive ($+$). This can be written as $PPV = P(D \\mid +)$.\n\nWe begin with Bayes’ theorem:\n$$\nP(D \\mid +) = \\frac{P(+ \\mid D) P(D)}{P(+)}\n$$\nThe terms in the numerator are given directly in the problem statement:\n-   $P(+ \\mid D) = Se$ (Sensitivity)\n-   $P(D) = p$ (Prevalence)\n\nThe denominator, $P(+)$, is the total probability of a positive test result. It can be expanded using the law of total probability by conditioning on the true biomarker status, $D$ or $\\neg D$:\n$$\nP(+) = P(+ \\mid D) P(D) + P(+ \\mid \\neg D) P(\\neg D)\n$$\nWe can express the terms in this expansion using the given definitions:\n-   $P(+ \\mid D) = Se$\n-   $P(D) = p$\n-   The probability of not having the biomarker is $P(\\neg D) = 1 - P(D) = 1 - p$.\n-   The term $P(+ \\mid \\neg D)$ is the probability of a positive test in a subject without the biomarker, which is the false positive rate. This can be derived from the specificity, $Sp$. Specificity is defined as $Sp = P(- \\mid \\neg D)$. Since for a given condition (here, $\\neg D$), the probabilities of all possible outcomes must sum to $1$, we have $P(+ \\mid \\neg D) + P(- \\mid \\neg D) = 1$. Therefore, $P(+ \\mid \\neg D) = 1 - Sp$.\n\nSubstituting these expressions back into the equation for $P(+)$:\n$$\nP(+) = (Se)(p) + (1 - Sp)(1 - p)\n$$\nNow, we substitute this full expression for $P(+)$ back into the Bayes' theorem for $PPV$:\n$$\nPPV(p, Se, Sp) = \\frac{Se \\cdot p}{Se \\cdot p + (1 - Sp)(1 - p)}\n$$\nThis is the general expression for the Positive Predictive Value as a function of prevalence $p$, sensitivity $Se$, and specificity $Sp$.\n\nNext, we use the provided values ($Se = 0.95$ and $Sp = 0.98$) to compute the $PPV$ for the two given prevalence values.\n\nFor the initial Phase II study, the prevalence is $p_1 = 0.05$. The corresponding $PPV_1$ is:\n$$\nPPV_1 = \\frac{0.95 \\cdot 0.05}{0.95 \\cdot 0.05 + (1 - 0.98)(1 - 0.05)}\n$$\n$$\nPPV_1 = \\frac{0.0475}{0.0475 + (0.02)(0.95)}\n$$\n$$\nPPV_1 = \\frac{0.0475}{0.0475 + 0.019}\n$$\n$$\nPPV_1 = \\frac{0.0475}{0.0665} \\approx 0.7142857...\n$$\nFor the later multicenter rollout with an enriched population, the prevalence is $p_2 = 0.20$. The corresponding $PPV_2$ is:\n$$\nPPV_2 = \\frac{0.95 \\cdot 0.20}{0.95 \\cdot 0.20 + (1 - 0.98)(1 - 0.20)}\n$$\n$$\nPPV_2 = \\frac{0.19}{0.19 + (0.02)(0.80)}\n$$\n$$\nPPV_2 = \\frac{0.19}{0.19 + 0.016}\n$$\n$$\nPPV_2 = \\frac{0.19}{0.206} \\approx 0.9223300...\n$$\nThe problem asks for the numerical change in $PPV$, which is $\\Delta PPV = PPV_2 - PPV_1$.\n$$\n\\Delta PPV = 0.9223300... - 0.7142857... = 0.2080443...\n$$\nRounding this result to four significant figures gives $0.2080$.\n\nThe clinical impact of this change is substantial. By enriching the patient population to increase biomarker prevalence from $0.05$ to $0.20$, the confidence that a positive test result correctly identifies a patient with the actionable mutation rises from a probability of approximately $0.71$ to $0.92$. This enhancement in predictive power is critical for clinical practice as it significantly reduces the number of patients who would be incorrectly identified for a targeted therapy (i.e., false positives). This improves patient safety by avoiding unnecessary exposure to potentially toxic treatments and ensures the therapy is more accurately allocated to the patient population most likely to derive a clinical benefit.", "answer": "$$\\boxed{0.2080}$$", "id": "5009047"}, {"introduction": "The ultimate validation of a companion diagnostic's clinical value is demonstrating a treatment-by-biomarker interaction in a pivotal clinical trial. This interaction provides the statistical evidence that a therapy's efficacy is significantly different in biomarker-positive patients compared to biomarker-negative patients. This practice [@problem_id:5009025] takes you to the heart of trial design for personalized medicine, challenging you to calculate the total sample size required to power a study to reliably detect this essential interaction effect, thereby substantiating the CDx's role in guiding treatment.", "problem": "A biotechnology company is co-developing a Companion Diagnostic (CDx) to identify patients likely to benefit from a targeted oncology therapy. The pivotal, two-arm randomized clinical trial is designed with equal allocation ($1:1$) to treatment and control, and will test whether the treatment effect differs by biomarker status. The primary endpoint is a continuous change score (e.g., change in tumor burden) measured once post-baseline, modeled as normally distributed with a common variance across all subgroups. The biomarker is binary with prevalence $\\pi$ in the target population. Randomization is independent of biomarker status.\n\nThe scientific estimand for the Companion Diagnostic (CDx) claim is the treatment-by-biomarker interaction, defined as the difference between the treatment effect in biomarker-positive and biomarker-negative patients. Consider the linear model\n$$\nY \\;=\\; \\mu \\;+\\; \\alpha\\,T \\;+\\; \\beta\\,B \\;+\\; \\gamma\\,(T\\cdot B) \\;+\\; \\varepsilon,\n$$\nwhere $Y$ is the continuous endpoint, $T \\in \\{0,1\\}$ is treatment assignment, $B \\in \\{0,1\\}$ is biomarker status, $\\gamma$ is the interaction parameter of interest, and $\\varepsilon \\sim \\mathcal{N}(0,\\sigma^{2})$. The biomarker prevalence is $\\pi$, so that the expected fractions of participants in the four cells $(B,T)\\in\\{0,1\\}^{2}$ are $(\\pi/2,\\pi/2,(1-\\pi)/2,(1-\\pi)/2)$.\n\nYou will test $H_{0}:\\gamma=0$ versus $H_{1}:\\gamma=\\Delta$ using a two-sided type I error $\\alpha$ with target power $1-\\beta$ under a large-sample Wald test, assuming known $\\sigma^{2}$. For planning, use the following scientifically justified quantities based on earlier phase data and clinical input:\n- Two-sided type I error: $\\alpha=0.05$.\n- Target power: $1-\\beta=0.90$.\n- Biomarker prevalence: $\\pi=0.30$.\n- Common standard deviation: $\\sigma=10$.\n- Clinically meaningful interaction effect: $\\Delta=5$.\n\nAssume independent and identically distributed sampling, no missing data, and independence of $T$ and $B$ due to randomization.\n\nCompute the minimum total sample size $n$ needed to achieve the specified power to detect the interaction $\\gamma=\\Delta$ at the given $\\alpha$. Report the smallest integer $n$ that satisfies the requirement. Do not express the answer with a percentage sign; provide a single integer count of participants.", "solution": "The problem requires the calculation of the minimum total sample size, $n$, for a two-arm randomized clinical trial designed to detect a statistically significant treatment-by-biomarker interaction effect.\n\nFirst, we establish the statistical framework. The problem specifies a large-sample Wald test for the interaction parameter, $\\gamma$, in the linear model:\n$$\nY \\;=\\; \\mu \\;+\\; \\alpha\\,T \\;+\\; \\beta\\,B \\;+\\; \\gamma\\,(T\\cdot B) \\;+\\; \\varepsilon\n$$\nThe null hypothesis is $H_{0}: \\gamma = 0$, and the alternative hypothesis is $H_{1}: \\gamma = \\Delta$, where $\\Delta$ is the clinically meaningful interaction effect. The test is two-sided with a type I error rate of $\\alpha$ and a desired power of $1-\\beta$.\n\nThe general formula for the required sample size in such a test is derived from the test statistic $Z = \\frac{\\hat{\\gamma}}{\\mathrm{SE}(\\hat{\\gamma})}$, where $\\hat{\\gamma}$ is the estimator for $\\gamma$ and $\\mathrm{SE}(\\hat{\\gamma})$ is its standard error. For a two-sided test, the required sample size $n$ must satisfy the equation:\n$$\nn = \\frac{(z_{1-\\alpha/2} + z_{1-\\beta})^2 \\sigma_{\\hat{\\gamma}, \\text{unit}}^2}{\\Delta^2}\n$$\nwhere $z_q$ is the $q$-th quantile of the standard normal distribution, $\\Delta$ is the effect size to be detected under $H_1$, and $\\sigma_{\\hat{\\gamma}, \\text{unit}}^2$ is the per-subject variance of the estimator, such that the variance of the estimator is $\\mathrm{Var}(\\hat{\\gamma}) = \\sigma_{\\hat{\\gamma}, \\text{unit}}^2 / n$. Our primary task is to determine $\\mathrm{Var}(\\hat{\\gamma})$.\n\nThe interaction parameter $\\gamma$ represents the difference in the treatment effect between biomarker-positive ($B=1$) and biomarker-negative ($B=0$) patients. Let $\\mu_{bt} = E[Y|B=b, T=t]$ be the expected outcome for biomarker status $b \\in \\{0,1\\}$ and treatment status $t \\in \\{0,1\\}$. From the linear model, we have:\n- Treatment effect in biomarker-positives: $(\\mu_{11} - \\mu_{10}) = (\\mu + \\alpha + \\beta + \\gamma) - (\\mu + \\beta) = \\alpha + \\gamma$\n- Treatment effect in biomarker-negatives: $(\\mu_{01} - \\mu_{00}) = (\\mu + \\alpha) - \\mu = \\alpha$\n\nThe interaction is the difference between these two treatment effects: $(\\alpha + \\gamma) - \\alpha = \\gamma$.\nThe least-squares estimator for $\\gamma$, assuming a balanced design, is the corresponding contrast of the four group sample means:\n$$\n\\hat{\\gamma} = (\\bar{Y}_{11} - \\bar{Y}_{10}) - (\\bar{Y}_{01} - \\bar{Y}_{00})\n$$\nwhere $\\bar{Y}_{bt}$ is the sample mean of the outcome in the group with $B=b$ and $T=t$. Since the four groups consist of independent samples, the variance of $\\hat{\\gamma}$ is the sum of the variances of the four sample means:\n$$\n\\mathrm{Var}(\\hat{\\gamma}) = \\mathrm{Var}(\\bar{Y}_{11}) + \\mathrm{Var}(\\bar{Y}_{10}) + \\mathrm{Var}(\\bar{Y}_{01}) + \\mathrm{Var}(\\bar{Y}_{00})\n$$\nThe variance of a sample mean from a group of size $n_{bt}$ is $\\sigma^2 / n_{bt}$, where $\\sigma^2$ is the common variance of the error term $\\varepsilon$. Therefore,\n$$\n\\mathrm{Var}(\\hat{\\gamma}) = \\frac{\\sigma^2}{n_{11}} + \\frac{\\sigma^2}{n_{10}} + \\frac{\\sigma^2}{n_{01}} + \\frac{\\sigma^2}{n_{00}} = \\sigma^2 \\left( \\frac{1}{n_{11}} + \\frac{1}{n_{10}} + \\frac{1}{n_{01}} + \\frac{1}{n_{00}} \\right)\n$$\nThe problem states that the total sample size is $n$, the biomarker prevalence is $\\pi$, and there is equal ($1:1$) allocation to treatment ($T=1$) and control ($T=0$). Due to the independence of randomization and biomarker status, the expected cell sizes are:\n- $n_{11}$ (Biomarker positive, Treatment): $n \\times \\pi \\times \\frac{1}{2} = \\frac{n\\pi}{2}$\n- $n_{10}$ (Biomarker positive, Control): $n \\times \\pi \\times \\frac{1}{2} = \\frac{n\\pi}{2}$\n- $n_{01}$ (Biomarker negative, Treatment): $n \\times (1-\\pi) \\times \\frac{1}{2} = \\frac{n(1-\\pi)}{2}$\n- $n_{00}$ (Biomarker negative, Control): $n \\times (1-\\pi) \\times \\frac{1}{2} = \\frac{n(1-\\pi)}{2}$\n\nSubstituting these into the variance formula:\n$$\n\\mathrm{Var}(\\hat{\\gamma}) = \\sigma^2 \\left( \\frac{1}{n\\pi/2} + \\frac{1}{n\\pi/2} + \\frac{1}{n(1-\\pi)/2} + \\frac{1}{n(1-\\pi)/2} \\right)\n$$\n$$\n\\mathrm{Var}(\\hat{\\gamma}) = \\sigma^2 \\left( \\frac{2}{n\\pi/2} + \\frac{2}{n(1-\\pi)/2} \\right) = \\sigma^2 \\left( \\frac{4}{n\\pi} + \\frac{4}{n(1-\\pi)} \\right)\n$$\n$$\n\\mathrm{Var}(\\hat{\\gamma}) = \\frac{4\\sigma^2}{n} \\left( \\frac{1}{\\pi} + \\frac{1}{1-\\pi} \\right) = \\frac{4\\sigma^2}{n} \\left( \\frac{(1-\\pi) + \\pi}{\\pi(1-\\pi)} \\right) = \\frac{4\\sigma^2}{n\\pi(1-\\pi)}\n$$\nNow we can construct the final sample size formula:\n$$\nn = \\frac{(z_{1-\\alpha/2} + z_{1-\\beta})^2}{\\Delta^2} \\times \\left( \\frac{4\\sigma^2}{\\pi(1-\\pi)} \\right) = \\frac{4\\sigma^2(z_{1-\\alpha/2} + z_{1-\\beta})^2}{\\Delta^2\\pi(1-\\pi)}\n$$\nWe are given the following values:\n- Type I error $\\alpha = 0.05$, so $1-\\alpha/2 = 0.975$. The corresponding z-score is $z_{0.975} \\approx 1.960$.\n- Power $1-\\beta = 0.90$, so $\\beta = 0.10$. The corresponding z-score is $z_{1-\\beta} = z_{0.90} \\approx 1.282$.\n- Common standard deviation $\\sigma = 10$, so $\\sigma^2 = 100$.\n- Clinically meaningful interaction effect $\\Delta = 5$, so $\\Delta^2 = 25$.\n- Biomarker prevalence $\\pi = 0.30$.\n\nSubstituting these values into the formula:\n$$\nn = \\frac{4 \\times 100 \\times (1.960 + 1.282)^2}{25 \\times 0.30 \\times (1 - 0.30)}\n$$\n$$\nn = \\frac{400 \\times (3.242)^2}{25 \\times 0.30 \\times 0.70}\n$$\n$$\nn = \\frac{400 \\times 10.510564}{25 \\times 0.21}\n$$\n$$\nn = \\frac{4204.2256}{5.25}\n$$\n$$\nn \\approx 800.804876\n$$\nSince the sample size must be an integer, we must round up to the next whole number to ensure the power requirement is met. Therefore, the minimum total sample size is $801$.", "answer": "$$\n\\boxed{801}\n$$", "id": "5009025"}]}